Login to Your Account

AACR 2013

Epigenetics Now Goes Far Beyond HDAC Inhibitors

By Anette Breindl
Science Editor

Monday, April 8, 2013

WASHINGTON – Several presentations at the American Association for Cancer Research's (AACR) Annual Meeting this week underscored the size of the epigenetic space. Targeting epigenetic alterations has gone far beyond histone deacetylase (HDAC) and DNA methyltransferase (DNMT) inhibitors, which are the two classes of epigenetic enzymes that have approved drugs targeting them.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription